Video

Dr. Sonpavde on Agents Under Investigation in PD-L1-Low Bladder Cancer

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1–low bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1—low bladder cancer.

There are trials being planned in that patient population, says Sonpavde, and time will tell whether or not the combination of chemotherapy and PD-1/PD-L1 inhibitors will be valuable in this setting. This approach also being looked at in ongoing phase III trials enrolling both cisplatin-eligible and -ineligible patients.

In addition, there is an Intergroup trial for cisplatin-ineligible patients that is comparing the combination of cisplatin and gemcitabine with or without bevacizumab (Avastin) or placebo. Those results are pending, adds Sonpavde. Finally, investigators are also looking into a “kitchen sink” approach in which several agents are being combined together, including durvalumab (Imfinzi) and tremelimumab—a PD-L1 inhibitor and a CLTA-4 inhibitor—plus platinum-based chemotherapy, compared with chemotherapy, or chemotherapy plus PD-L1 inhibition alone.

Related Videos
Omid Hamid, MD
Marlana M. Orloff, MD
Mark Faries, MD
6368672538112
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Rene Y. McNall-Knapp, MD, pediatric hematologist-oncologist, Jimmy Everest Center, Oklahoma Children’s Hospital OU Health; professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
John Andrew Livingston, MD, MS
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Kathleen N. Moore, MD, MS